Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "work type" (1) AND "fulltext" AND "organization" (Institute of Oncology) .

141 - 150 / 3800
First pagePrevious page11121314151617181920Next pageLast page
141.
Assessment of differential expression of oncogenes in adenocarcinoma of stomach with fluorescent labeling and simultaneous amplification of gene transcripts
Uroš Rajčević, Petra Hudler, Gordan Mijovski, Gregor Gorjanc, Georg Hölzl, Stanislav Repše, Robert Juvan, Milena Kovač, Christian G. Huber, Radovan Komel, 2007, original scientific article

Abstract: Background. Gastric cancer is one of the leading malignancies with a poor prognosis and low survival rates. Although the mechanisms underlying its development are still unknown, there is a consensus that genetic instability, inactivation of tumor suppressor genes and over-expression of oncogenes are involved in the early and late stages of gastric carcinogenesis. In the present study we wanted to display differential expression of seven oncogenes,namely CCNE1, EGF, ERBB3, FGF4, HRG1, HGFR and TDGF1. Patients and methods. We employed a method based on the multiplex reverse transcription polymerase chain (RT-PCR) method with a fluorescence detection. Results. More than half of patients (74.3%) out of total 74 with gastric adenocarcinoma had over-expressed at least one oncogene, with the exception of FGF4, which was expressed in tumor tissue of less than one third of patients. 56.8% of the patients patients showed over-expression of two or more oncogenes. Conclusions. Patients with precancerous lesions had elevated levels of TDGF1 or cripto-1 (64.9%) and CCNE1 (57.1%), suggesting that they could be used as markers for an early detection of malignant changes in stomach. Finally, the fluorescent multiplex RT-PCR method could be of value for rapid assessment of oncogene mRNA levels in small samples of tumor or precancerous biopsies.
Published in DiRROS: 20.02.2024; Views: 94; Downloads: 27
.pdf Full text (86,60 KB)

142.
Subchronic exposure of rats to sublethal dose of microcystin-YR induces DNA damage in multiple organs
Metka Filipič, Bojana Žegura, Bojan Sedmak, Irena Horvat-Žnidaršič, Aleksandra Milutinović Živin, Dušan Šuput, 2007, original scientific article

Abstract: Background. Microcystins (MCs) are cyclic heptapeptides that are considered tobe liver specific toxins. They are potent tumour promoters and recent studies indicate that they are also genotoxic. In this study we measured DNA damage in lymphocytes, liver, kidney (cortex and medulla), lung, spleen and brain cells of male Fisher F344 rats that were exposed to sublethal dose (every second day 10 Ugžkg b.w.č i.p) of microeysrin-YR (MCYR) for one month. Methods. At the end of exposure the animals were sacrificed, the lymphocytes were isolated from blood taken from jugular vein, liver cells were obtained byperfusion with collagenase A and the cells from other organs were isolated by incubating small tissue pieces with eollagenase A. The DNA damage in isolated cells was measured with the single cells gel electrophoresis (SCGE) also called the comet assay. Results. A significant increase of the % tail DNAin MCYR-exposed animals compared to the nonexposed control ones was observed in brain (2.5 fold), liver (2.1 fold), kidney medulla (1.9 fold), kidney cortex (1.8 fold) and lung (1.7 fold) cells, while the DNA from lymphocytes and spleen cells was not affected. Conclusion. This study demonstrated that subehronic exposure to sublethal doses of MCs can induce systemicgenotoxicity in mammals, and it affects not only the liver but also other vital organs.
Keywords: DNA damage, comet assay, cyanobacteria, bacterial toxins, rats, inbred F344
Published in DiRROS: 20.02.2024; Views: 105; Downloads: 28
.pdf Full text (142,90 KB)

143.
The role of sentinel lymph node detection in vulvar carcinoma and the experiences at the Institute of Oncology Ljubljana
Aleš Vakselj, Sonja Bebar, 2007, original scientific article

Published in DiRROS: 20.02.2024; Views: 86; Downloads: 14
.pdf Full text (371,41 KB)

144.
Mb. Bowen and squamous-cell carcinoma on the eczematous skin
Boris Jančar, 2007, professional article

Published in DiRROS: 20.02.2024; Views: 95; Downloads: 20
.pdf Full text (131,84 KB)

145.
In vivo dosimetry with diodes in rectal cancer patients
Andrej Strojnik, 2007, original scientific article

Published in DiRROS: 20.02.2024; Views: 80; Downloads: 16
.pdf Full text (186,07 KB)

146.
Kidney cancer
Mirjana Rajer, 2007, professional article

Published in DiRROS: 20.02.2024; Views: 94; Downloads: 24
.pdf Full text (213,38 KB)

147.
Basal cell carcinoma on the left cheek
Boris Jančar, 2007, professional article

Published in DiRROS: 20.02.2024; Views: 94; Downloads: 25
.pdf Full text (1,83 MB)

148.
Basic Clinical Radiobiology Course Ljubljana (Slovenia), 21.-25. May 2006 : view from local participant
Mirjana Rajer, 2007, other component parts

Published in DiRROS: 20.02.2024; Views: 90; Downloads: 26
.pdf Full text (66,97 KB)

149.
Editoral [!]
Gregor Serša, 2007, preface, editorial, afterword

Published in DiRROS: 20.02.2024; Views: 85; Downloads: 28
.pdf Full text (29,27 KB)

150.
Paratesticular adenocarcinoma : unusual presentation of metastasis of pancreatic cancer
Janja Ocvirk, Boštjan Šeruga, 2007, short scientific article

Abstract: Background. Metastatic paratesticular adenocarcinoma from the pancreatic cancer is very rare. To our knowledge, there are less than 20 cases published in the literature. Case report. We experienced a case of paratesticular adenocarcinoma from the primary pancreatic cancer. A 42-year-old man was presented with locoregionally advanced carcinoma of the tail of the pancreas with intraoperatively found liver metastases and with a tumour in the right hemi-scrotum. Ultrasound of the scrotum revealed a paratesticular tumour. A fine needle aspiration biopsy (FNAB) confirmed a poorly differentiated adenocarcinoma and it was in concordance with the diagnosis of the primary tumour. The patient started treatment with chemotherapy with gemcitabine. Unfortunately, he progressed one month later and the treatment was discontinued. Conclusions. Outcome in the adenocarcinoma of the pancreas is dismal. The only possible treatment option for metastatic disease is systemic therapy but the results are disappointing, as in the present case.
Published in DiRROS: 19.02.2024; Views: 86; Downloads: 26
.pdf Full text (78,71 KB)

Search done in 1.67 sec.
Back to top